Showing results (51-60 of 74) with videos related to

Sort By:
Pageof 8
Genomics|November 1, 1992
A bone morphogenetic protein subfamily: chromosomal localization of human genes for BMP5, BMP6, and BMP7G V Hahn, R B Cohen, J M Wozney, et al.
Biochemical and Biophysical Research Communications|June 30, 1992
The endothelin receptor antagonist, BQ-123, inhibits angiotensin II-induced contractions in rabbit aortaM L Webb, K E Dickinson, C L Delaney, et al.
Clinical Orthopaedics and Related Research|August 1, 1993
Chromosomal assignment of the human gene for bone morphogenetic protein 4J A Tabas, G V Hahn, R B Cohen, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|March 20, 2015
Phase I study of every 2- or 3-week dosing of ramucirumab, a human immunoglobulin G1 monoclonal antibody targeting the vascular endothelial growth factor receptor-2 in patients with advanced solid tumorsE G Chiorean, H I Hurwitz, R B Cohen, et al.
The Journal of Bone and Joint Surgery. American Volume|February 1, 1993
The natural history of heterotopic ossification in patients who have fibrodysplasia ossificans progressiva. A study of forty-four patientsR B Cohen, G V Hahn, J A Tabas, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|December 20, 2014
A randomized, phase II trial of cetuximab with or without PX-866, an irreversible oral phosphatidylinositol 3-kinase inhibitor, in patients with relapsed or metastatic head and neck squamous cell cancerA Jimeno, K Shirai, M Choi, et al.
Peptides|May 1, 1992
Molecular characterization of angiotensin II type II receptors in rat pheochromocytoma cellsM L Webb, E C Liu, R B Cohen, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 1, 1995
Phase I/II study of intermittent all-trans-retinoic acid, alone and in combination with interferon alfa-2a, in patients with epidemic Kaposi's sarcomaJ Bailey, J M Pluda, A Foli, et al.
Cancer Chemotherapy and Pharmacology|September 13, 2014
A first-in-human study of the anti-α5β1 integrin monoclonal antibody PF-04605412 administered intravenously to patients with advanced solid tumorsJ Mateo, J Berlin, J S de Bono, et al.
Annals of Surgery|February 1, 1985
The use of pathologic features in selecting the extent of surgical resection necessary for breast cancer patients treated by primary radiation therapyJ R Harris, J L Connolly, S J Schnitt, et al.
Pageof 8